Sanofi has replaced its CEO Paul Hudson after a series of R&D setbacks at the French pharma, handing the reins to Merck KGaA leader Belén Garijo, M.D., Ph.D.

Sanofi has replaced chief executive Paul Hudson with the head of German drugmaker Merck KGaA, after the French drugmaker ...

Merck KGaA stock: what recent performance says about investor sentiment Merck KGaA (XTRA:MRK) has seen a mix of outcomes for shareholders, with a 3.3% year to date return, a 5.1% decline over the past ...

The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent months, including GSK’s Emma Walmsley and Novo Nordisk’s Lars Fruergaard ...

The move drew skepticism from investors despite multiple recent research setbacks that have left questions about Sanofi’s ability to confront Dupixent’s looming patent expiration.

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Merck KGaA ...

Dr. Rasha Kelej announced that 29 scholarships have been provided to Senegalese doctors in critical specialties including ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Despite a rocky start to the year for Merck KGaA’s contract development and manufacturing group, the German company is finding some reason to be optimistic about its recent performance. Last week, ...

Drugs that interfere with a way tumors repair damage to their DNA have become valuable tools for treating certain cancers. Some big pharmaceutical companies are developing drugs that improve on this ...

Merck KGaA is an undervalued pharma company with a long history and strong fundamentals. The company has above-average margins and a diverse business portfolio in healthcare, life sciences, and ...

Big pharma performed well in 2022, but the time to trim is drawing close. As a more diversified investment, I believe former parent company of Merck & Co, Merck KGaA offers a better long-term ...